Literature DB >> 29736309

MicroRNA-876-3p functions as a tumor suppressor gene and correlates with cell metastasis in pancreatic adenocarcinoma via targeting JAG2.

Fu Yang1, Wan Jun Zhao2, Cong Li Jia3, Xiao Kai Li1, Qiang Wang1, Zi Li Chen4, De Quan Jiang5.   

Abstract

Dysregulation of microRNA (miRNA) expression in multiple cancers and their vital roles in malignant cancer progression are well investigated. The purpose of this study was to explore the biological roles of miR-876-3p in pancreatic cancer. We used genome-wide gene expression analysis in clinical pancreatic adenocarcinoma samples to identify miR-876-3p down-regulated in pancreatic cancer. We then collected 22 pairs of pancreatic cancer and the corresponding non-cancerous tissues to determine miR-876-3p level, and confirmed that miR-876-3p was significantly down-regulated in pancreatic cancer. Furthermore, functional analysis suggested that overexpression of miR-876-3p suppressed cell growth and aggressively increased cells apoptosis in BXPC-3 and PANC-1 cells, whereas down-regulation led to the opposite results. We identified Jagged2 (JAG2) as a direct target of miR-876-3p, and an inverse correlation between miR-876-3p and JAG2 was observed in pancreatic adenocarcinoma. Moreover, miR-876-3p and a JAG2 siRNA were co-transfected into both PANC-1 and BXPC-3 cells to explore the mechanism of miR-876-3p and JAG2 on pancreatic adenocarcinoma tumorigenesis. Down-regulation of JAG2 inhibited the overexpression effects of miR-876-3p, and up-regulation of JAG2 reversed the effects of overexpressed miR-876-3p. Cumulatively, these results revealed a significant role of the miR-876-3p/JAG2 axis in suppressing pancreatic adenocarcinoma cell growth and aggressiveness.

Entities:  

Keywords:  JAG2; aggressiveness; miR-876-3p; pancreatic adenocarcinoma

Year:  2018        PMID: 29736309      PMCID: PMC5934554     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  24 in total

1.  Anticancer effect and apoptosis induction by quercetin in the human lung cancer cell line A-549.

Authors:  Shi-Ying Zheng; Yin Li; Dong Jiang; Jun Zhao; Jin-Feng Ge
Journal:  Mol Med Rep       Date:  2011-12-20       Impact factor: 2.952

2.  YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway.

Authors:  Dongfang Liu; Jingjing Zhang; Yang Wu; Guodong Shi; Hao Yuan; Zipeng Lu; Qicong Zhu; Pengfei Wu; Cheng Lu; Feng Guo; Jianmin Chen; Kuirong Jiang; Yi Miao
Journal:  Int J Cancer       Date:  2017-12-04       Impact factor: 7.396

3.  MiRNAs are Unlikely to be Involved in Retinoid Receptor Gene Regulation in Pancreatic Cancer Cells.

Authors:  Shuai Yin; Tim Bleul; Yifan Zhu; Orkhan Isayev; Jens Werner; Alexandr V Bazhin
Journal:  Cell Physiol Biochem       Date:  2017-11-24

Review 4.  Matricellular proteins and survival in patients with pancreatic cancer: A systematic review.

Authors:  Sirio Fiorino; Maria Letizia Bacchi-Reggiani; Chiara Birtolo; Giorgia Acquaviva; Michela Visani; Adele Fornelli; Michele Masetti; Andrea Tura; Stefano Sbrignadello; Fabio Grizzi; Federica Patrinicola; Matteo Zanello; Laura Mastrangelo; Raffaele Lombardi; Claudia Benini; Luca Di Tommaso; Arrigo Bondi; Francesco Monetti; Elena Siopis; Paolo Emilio Orlandi; Michele Imbriani; Carlo Fabbri; Silvia Giovanelli; Andrea Domanico; Esterita Accogli; Salomone Di Saverio; Daniela Grifoni; Vincenzo Cennamo; Paolo Leandri; Elio Jovine; Dario de Biase
Journal:  Pancreatology       Date:  2017-11-04       Impact factor: 3.996

Review 5.  Pancreatitis and Pancreatic Cancer.

Authors:  Anne Walling; Robert Freelove
Journal:  Prim Care       Date:  2017-10-05       Impact factor: 2.907

6.  A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.

Authors:  Fengfei Wang; Marc Remke; Kruttika Bhat; Eric T Wong; Shuang Zhou; Vijay Ramaswamy; Adrian Dubuc; Ekokobe Fonkem; Saeed Salem; Hongbing Zhang; Tze-Chen Hsieh; Stephen T O'Rourke; Lizi Wu; David W Li; Cynthia Hawkins; Isaac S Kohane; Joseph M Wu; Min Wu; Michael D Taylor; Erxi Wu
Journal:  Oncotarget       Date:  2015-02-20

7.  MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor.

Authors:  Praneeth R Kuninty; Linda Bojmar; Vegard Tjomsland; Marie Larsson; Gert Storm; Arne Östman; Per Sandström; Jai Prakash
Journal:  Oncotarget       Date:  2016-03-29

8.  High expression of the Notch ligand Jagged-1 is associated with poor prognosis after surgery for colorectal cancer.

Authors:  Masakazu Sugiyama; Eiji Oki; Yu Nakaji; Satoshi Tsutsumi; Naomi Ono; Ryota Nakanishi; Masahiko Sugiyama; Yuichiro Nakashima; Hideto Sonoda; Kippei Ohgaki; Nami Yamashita; Hiroshi Saeki; Shinji Okano; Hiroyuki Kitao; Masaru Morita; Yoshinao Oda; Yoshihiko Maehara
Journal:  Cancer Sci       Date:  2016-11       Impact factor: 6.716

9.  Jagged-2 enhances immunomodulatory activity in adipose derived mesenchymal stem cells.

Authors:  Zhu Xishan; Zhang Bin; Zhao Haiyue; Dou Xiaowei; Bai Jingwen; Zhang Guojun
Journal:  Sci Rep       Date:  2015-09-28       Impact factor: 4.379

10.  Jagged-2 (JAG2) enhances tumorigenicity and chemoresistance of colorectal cancer cells.

Authors:  Vivek Vaish; Joohwee Kim; Minsub Shim
Journal:  Oncotarget       Date:  2017-06-07
View more
  10 in total

1.  miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway.

Authors:  Yuki Takagawa; Yasuyuki Gen; Tomoki Muramatsu; Kousuke Tanimoto; Jun Inoue; Hiroyuki Harada; Johji Inazawa
Journal:  Mol Ther       Date:  2020-04-11       Impact factor: 11.454

2.  Silencing LINC00504 inhibits cell proliferation, invasion as well as migration and promotes cell apoptosis in lung cancer cells via upregulating miR-876-3p.

Authors:  Zhen Zhang
Journal:  Cytotechnology       Date:  2020-10-08       Impact factor: 2.058

3.  Circ_0016760 Serves as a Cancer Promoter in Non-small Cell Lung Cancer Through miR-876-3p/NOVA2 Axis.

Authors:  Fengjie Liu; Haiying Gao; Mingwei Chen; Anqi Li; Ting Liu
Journal:  Biochem Genet       Date:  2022-03-03       Impact factor: 1.890

4.  The cuproptosis-related gene signature serves as a potential prognostic predictor for ovarian cancer using bioinformatics analysis.

Authors:  Xin Sun; Panling Xu; Fengli Zhang; Ting Sun; Haili Jiang; Xinyuan Lu; Mei Zhang; Ping Li
Journal:  Ann Transl Med       Date:  2022-09

5.  CircLNPEP promotes the progression of ovarian cancer through regulating miR-876-3p/ WNT5A axis.

Authors:  Wenwen Wang; Weiwei Zhang; Hongjun Guo; Danxia Chu; Ruitao Zhang; Ruixia Guo
Journal:  Cell Cycle       Date:  2021-08-31       Impact factor: 5.173

6.  Mutual regulation of JAG2 and PRAF2 promotes migration and invasion of colorectal cancer cells uncoupled from epithelial-mesenchymal transition.

Authors:  Wan He; Jun Tang; Wenwen Li; Yong Li; Yi Mei; Lisheng He; Keli Zhong; Ruilian Xu
Journal:  Cancer Cell Int       Date:  2019-06-11       Impact factor: 5.722

7.  Dysregulation of SPRR3/miR-876-3p Axis Contributes to Tumorigenesis in Non-Small-Cell Lung Cancer.

Authors:  Qin Li; Yuxuan Wang; Rongkuan Hu; Guang Yang
Journal:  Onco Targets Ther       Date:  2020-03-23       Impact factor: 4.147

8.  The Involvement of the hsa_circ_0088494-miR-876-3p-CTNNB1/CCND1 Axis in Carcinogenesis and Progression of Papillary Thyroid Carcinoma.

Authors:  Weiyang Lou; Bisha Ding; Jiannan Wang; Yongfang Xu
Journal:  Front Cell Dev Biol       Date:  2020-12-09

9.  LINC00504 Promotes the Malignant Biological Behavior of Breast Cancer Cells by Upregulating HMGB3 via Decoying MicroRNA-876-3p.

Authors:  Hao Yu; Liqian Dong; Hongyu Wang; Yang Zhang; Zhuo Wang; Can Wang; Hong Xia; Huizheng Bao
Journal:  Cancer Manag Res       Date:  2021-02-22       Impact factor: 3.989

10.  Circ-RNF111 aggravates the malignancy of gastric cancer through miR-876-3p-dependent regulation of KLF12.

Authors:  Guoxian Wu; Aimin Zhang; Yinglin Yang; Dongping Wu
Journal:  World J Surg Oncol       Date:  2021-08-30       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.